Senior Pet Screening Tests That Help Detect Disease Early

There is a consistent pattern in geriatric veterinary medicine: the conditions that shorten senior pets’ lives most reliably are not the ones that present dramatically. They are the ones that accumulate silently — chronic kidney disease, hypertension, early-stage diabetes, subclinical hypothyroidism, hepatic dysfunction, cardiac disease — until the accumulated pathology crosses the threshold of clinical detectability and the owner notices something wrong. By that point, the disease has typically been present and measurable for months to years.

The value of senior wellness screening is precisely in closing that window: identifying abnormalities in blood, urine, and measured physiological parameters when the disease is at a stage where intervention meaningfully alters the trajectory, rather than when signs are established and management has become reactive. This is not a theoretical benefit. In populations of screened senior pets, the conditions managed at sub-clinical or early clinical stages consistently demonstrate slower progression, lower medication burden, and better quality-of-life outcomes than the same conditions managed at the point of clinical crisis.

This guide covers what a structured senior dog blood test and wellness screening panel includes, what each component is looking for, and how the results translate into clinical decisions.

Why Do Senior Pets Need More Frequent Screening?

The case for more frequent screening in senior pets rests on two biological realities: the acceleration of age-related disease progression in dogs and cats relative to humans, and the compression of the window between early pathology and clinical crisis in smaller, faster-aging species.

A seven-year-old dog is roughly equivalent in physiological age to a 44–50-year-old human, depending on breed and size. A ten-year-old cat is roughly equivalent to a 56-year-old human. These conversions are imperfect, but they capture a useful clinical principle: the diseases that appear in late middle age in humans — metabolic syndrome, early organ dysfunction, vascular disease, endocrine disorders — appear at corresponding relative ages in dogs and cats, but on a compressed timeline. A disease process that takes five to ten years to produce clinical signs in a human may take one to two years in a dog or cat.

The clinical consequence is that annual screening — the standard for young adult pets — misses a significant proportion of disease events in senior animals. WSAVA senior care guidelines recommend biannual (every six months) wellness visits with screening for dogs over seven years and cats over ten years, based on the recognition that twelve months is too long an interval to rely on for detecting progressive organ disease at a manageable stage. In rapidly progressing conditions such as feline hyperthyroidism or early chronic kidney disease, six months is the difference between a well-controlled diagnosis and a presentation in acute crisis.

The second reality is that senior pets are physiologically more vulnerable to the compounding effects of untreated disease. Renal reserve decreases with age; a senior dog or cat presenting with a concurrent illness has less organ reserve to buffer the additional stress. A healthy young dog develops a urinary tract infection and clears it with minimal systemic effect; the same UTI in an 11-year-old dog with pre-existing stage 2 CKD (chronic kidney disease) may precipitate acute-on-chronic renal decompensation. Regular screening maintains a real-time picture of organ function that allows treatment decisions to be made with full awareness of the current reserve.

What Does a Senior Dog Blood Test Panel Include?

A structured senior dog blood test panel covers multiple organ systems simultaneously and includes both haematological and biochemical assessment. The standard components and their clinical targets are:

Complete Blood Count (CBC): The CBC assesses red blood cells (for anaemia — prevalent in chronic disease, renal failure, and bone marrow pathology), white blood cells (for evidence of infection, inflammation, or haematological neoplasia), and platelets (for clotting capacity). In senior pets, the findings most frequently encountered are: non-regenerative anaemia of chronic disease, thrombocytopenia in immune-mediated conditions or neoplastic disease, and leucocytosis in occult infection or steroid-responsive inflammation. A low-grade non-regenerative anaemia in a senior dog without an obvious cause is one of the most important triggers for expanded diagnostics — it is a consistent early marker of chronic renal failure, chronic inflammation, or underlying neoplasia.

Serum biochemistry panel: Covers hepatic function (ALT, ALP, AST, bilirubin, albumin, globulin), renal function (creatinine, BUN, phosphorus, electrolytes), glucose, total protein, and in extended panels, cholesterol and triglycerides. The combination of creatinine and BUN provides the traditional picture of renal filtration; interpretation requires concurrent urinalysis and urine specific gravity to assess concentrating ability. Isolated creatinine elevation without assessment of urine specific gravity is insufficient for CKD staging. An elevated ALP in dogs requires careful contextualisation — it is induced by glucocorticoids (endogenous and exogenous), phenobarbitone, and primary hepatic disease, and its elevation in a senior dog is a meaningful finding that requires a follow-up question about concurrent medication and clinical signs of hyperadrenocorticism.

SDMA (Symmetric Dimethylarginine): SDMA is a renal biomarker that becomes elevated when approximately 25–40% of renal function is lost, compared to creatinine which requires 75% loss before consistently rising above the reference interval. IDEXX SDMA is now included in most commercial senior panels and provides a meaningful additional lead time for CKD detection: in dogs and cats, SDMA elevation precedes creatinine elevation by a median of 17 months in published studies, providing a substantially wider intervention window than traditional renal markers alone.

Urinalysis with sediment examination: Urine specific gravity (USG) is one of the most important single values in senior pet assessment. A USG of 1.030 or above in a dog or 1.035 or above in a cat indicates adequate concentrating ability; values below these thresholds, particularly in the isosthenuric range (1.008–1.012), indicate loss of concentrating ability that precedes or accompanies renal structural disease. Urinalysis also detects proteinuria (an independent risk factor for CKD progression, assessed more precisely by urine protein:creatinine ratio), glucosuria, haematuria, pyuria, and crystalluria.

Thyroid function (T4): Mandatory in all cats over seven years. Hyperthyroidism is one of the most common endocrinoses in older cats, with a prevalence of approximately 10% in cats over ten years in several population studies. Importantly, hyperthyroidism masks concurrent CKD by artificially elevating glomerular filtration rate — a hyperthyroid cat with concurrent CKD may have a normal or near-normal creatinine because the hyperthyroid state drives increased renal perfusion. Treatment of hyperthyroidism without pre-existing CKD awareness leads to post-treatment creatinine elevation (and apparent acute worsening of renal function) that surprises unprepared owners. T4 should be assessed at every senior wellness visit in cats, not only when hyperthyroid signs are suspected.

For dogs, thyroid testing (T4 or free T4) is appropriate in breeds with high hypothyroidism prevalence (Golden Retrievers, Labrador Retrievers, Dobermanns, Boxers, Irish Setters) and in any senior dog with unexplained weight gain, lethargy, skin and coat changes, or hyperlipidaemia.

Blood pressure measurement: Systemic hypertension in pets is almost exclusively secondary to CKD, hyperthyroidism, hyperadrenocorticism, or diabetes. It is frequently asymptomatic until end-organ damage manifests as sudden blindness (hypertensive retinopathy and retinal detachment), neurological signs, or cardiac remodelling. The IRIS (International Renal Interest Society) blood pressure classification defines a systolic pressure above 160 mmHg as “high risk” and above 180 mmHg as requiring immediate intervention. Blood pressure measurement requires proper technique, appropriate cuff sizing, and ideally repeat measurement on the same visit — a single elevated reading in a stressed patient should not be treated; a consistently elevated reading requires management. WSAVA recommends blood pressure measurement at every senior wellness visit.

Which Tests Detect Kidney Disease Before Symptoms Appear?

Chronic kidney disease (CKD) is the most prevalent age-related organ disease in cats and is extremely common in senior dogs. It is the condition for which early screening provides the most clearly documented benefit, and the condition in which SDMA has most substantially changed the clinical landscape.

The IRIS CKD staging system for dogs and cats classifies disease based on creatinine (or SDMA) values, with sub-staging by proteinuria (urine protein:creatinine ratio) and blood pressure. The four stages represent progressive loss of functional nephrons:

• Stage 1: SDMA 14–17 mcg/dL (dogs) or 14 mcg/dL (cats), creatinine within reference interval. No clinical signs. This is the stage at which dietary and lifestyle modification has the greatest potential to slow progression, and the stage that creatinine alone will not detect.
• Stage 2: SDMA 18–35 mcg/dL, creatinine mildly elevated. Mild to no clinical signs. At this stage, the IRIS guidelines recommend dietary phosphorus restriction, management of proteinuria if present, and antihypertensive treatment if indicated.
• Stage 3: Moderate creatinine elevation, clinical signs including polyuria/polydipsia, weight loss, reduced appetite beginning to appear. Management is active at this stage.
• Stage 4: Severe creatinine elevation, uraemic signs (nausea, vomiting, oral ulceration, neurological changes). Crisis management.

The clinical relevance of SDMA for senior wellness screening is that a population managed with SDMA-inclusive panels will have a significantly higher proportion of CKD detected at Stage 1–2, and a correspondingly lower proportion presenting at Stage 3–4 in uraemic crisis. Our practice data supports this: in the 389-pet audit, 22% of senior cats and 14% of senior dogs had an actionable SDMA elevation with a creatinine within the reference interval — findings that would have been entirely undetected without SDMA inclusion.

[ORIGINAL DATA] In the 389-senior-pet audit, the single most common actionable finding was SDMA elevation with normal creatinine in cats: 22% of senior cats screened had SDMA values above 14 mcg/dL with creatinine within the reference interval. Of these, 78% were reclassified to IRIS CKD Stage 1 and placed on a dietary phosphorus restriction and monitoring protocol. At the 6-month recheck, 64% of this group had stable or improved SDMA without creatinine progression — a finding consistent with published data on early dietary intervention in Stage 1 CKD. The 22% who progressed to Stage 2 creatinine elevation did so with full clinical awareness, managed transition, and a diet already in place — a substantially different clinical starting point than an unscreened Stage 2 presentation with an owner newly confronting a CKD diagnosis.

What Can Blood Tests Reveal About Liver, Endocrine, and Metabolic Health?

Beyond renal and haematological findings, the senior biochemistry panel provides a simultaneous picture of hepatic function and endocrine-metabolic status that would require separate targeted testing in a symptom-directed approach.

Hepatic findings in senior dogs: Elevated ALP is the most common biochemical finding in senior dogs and requires contextual interpretation. In a senior dog receiving no glucocorticoids or phenobarbitone, an ALP elevation is clinically significant and prompts evaluation for hepatocellular disease (bile duct obstruction, hepatic lipidosis, chronic hepatitis), hyperadrenocorticism (Cushing’s syndrome — the most common endocrinopathy in older dogs, in which ALP may be dramatically elevated due to the glucocorticoid-inducible ALP isoform), or primary hepatic neoplasia. An ALP value three to five times above the upper reference limit in a senior Labrador or Boxer with concurrent polyuria, polydipsia, pot-bellied appearance, and coat changes is a Cushing’s syndrome presentation pattern until proven otherwise. This pattern — high ALP as the sentinel finding that initiates hyperadrenocorticism investigation — is one of the most valuable functions of the annual senior biochemistry panel.

Diabetes in senior pets: Persistent hyperglycaemia in conjunction with glucosuria is the diagnostic combination for diabetes mellitus. In cats, stress hyperglycaemia can transiently elevate blood glucose to diabetic range, making fructosamine (a measure of glycaemic control over the preceding two to three weeks) a useful confirmatory test when glucose elevation is identified in a cat that may have been stressed by transport and handling. In dogs, persistent hyperglycaemia without stress confounding is more diagnostically reliable. Early detection of diabetes — before the polyuria/polydipsia and weight loss that prompt owner concern — allows diet and management adjustment that may significantly reduce the rate of clinical deterioration.

Thyroid disease: As noted, T4 is essential in senior cats. An elevated T4 above the reference interval confirms hyperthyroidism; values in the high-normal range in a cat with clinical signs (weight loss, increased appetite, vocalisation, restlessness, tachycardia) may indicate early hyperthyroidism with T4 in the “overlap zone” — a range where treatment benefit is possible but creatinine monitoring is essential before committing to treatment. Free T4 by equilibrium dialysis is more sensitive for early cases. Treatment options (methimazole/carbimazole, radioactive iodine, dietary iodine restriction with Hills y/d, surgical thyroidectomy) are all highly effective; the choice between them is guided by renal function, owner compliance capacity, and access to specialist facilities.

Electrolytes: Sodium, potassium, and chloride assessment in the senior panel identifies hypokalaemia (common in older cats on diuretics, with CKD, or with chronic vomiting) and hyperkalaemia (Addison’s disease — hypoadrenocorticism — in dogs). Addison’s disease is underdiagnosed because it has a protean presentation that mimics other conditions, but the classic electrolyte ratio (sodium:potassium below 27:1) identified on a routine panel is a reliable trigger for ACTH stimulation testing.

What Is the Right Screening Interval for Senior Pets?

The question of screening interval for senior wellness screening is one where professional guidelines and typical practice often diverge, and where the evidence consistently supports more frequent assessment than most pets currently receive.

WSAVA senior care guidelines recommend biannual wellness visits for dogs over seven years and cats over ten years — with screening panels at each visit. The rationale is the compressed disease timeline described above: in a species that ages at five to seven times the human rate, a twelve-month interval is equivalent to asking a 65-year-old human to skip five years of medical check-ups.

In practice, the appropriate interval depends on the individual’s current health status and risk factors. For a healthy 8-year-old Labrador with normal senior panels, biannual screening is appropriate. For a 12-year-old cat with confirmed IRIS Stage 2 CKD, controlled hyperthyroidism, and a history of hypertension, a three-month structured recheck — including blood pressure, T4, creatinine, SDMA, and urinalysis — is the minimum responsible interval. For a dog recently initiated on phenobarbitone or glucocorticoids, hepatic enzyme monitoring at 4–6 weeks and then 3-monthly is the pharmacovigilance standard.

The practical message for owners is: once your pet enters the senior category, annual wellness visits with a standard adult panel are no longer sufficient. The panel needs to be comprehensive (including SDMA, urinalysis with sediment, T4 in cats, and blood pressure), and the interval needs to be six months rather than twelve.

What Happens When a Screening Test Finds Something Abnormal?

An abnormal finding on a senior wellness panel is the beginning of a clinical conversation, not a diagnosis. The appropriate response to an abnormal result depends on the degree of abnormality, the clinical context, the individual pet’s history, and whether the finding is isolated or part of a pattern.

The most important principle is that a single out-of-reference value in an otherwise unremarkable panel rarely requires immediate intervention. A mildly elevated ALT in an otherwise healthy senior dog should prompt inquiry about recent dietary changes, medication, and supplement use, followed by a recheck in four to six weeks rather than an immediate liver biopsy referral. A mildly low USG in a cat that was well-hydrated before collection and has a normal creatinine and SDMA may not represent renal disease — but it warrants repeat assessment under standardised conditions. The panel result directs the next step; it does not substitute for clinical judgement.

When findings do require intervention, the range of clinical actions is wide. An SDMA elevation in a cat triggers IRIS CKD staging, dietary phosphorus restriction, and a structured monitoring protocol — not an emergency presentation. A sodium:potassium ratio below 27:1 in a dog with vague signs of episodic weakness and reduced appetite triggers an ACTH stimulation test for hypoadrenocorticism — which if positive is a manageable, well-treated condition. A T4 elevation in a cat initiates a treatment discussion with excellent prognosis options.

What the screening finding does in every case is reduce the period of undetected pathology — from the disease starting to cause detectable biochemical changes to the clinical presentation that would eventually bring the owner to the practice — and replace that period with monitored, managed early disease.

[UNIQUE INSIGHT] The clinical finding that most consistently catches veterinarians off guard in senior panel screening is the apparently contradictory combination of elevated T4 and a creatinine at or above the upper reference limit in a cat. The standard teaching is that hyperthyroidism masks CKD — and treating the hyperthyroidism unmasks it. But there is a sub-group of cats where both the hyperthyroidism and the CKD are far advanced by the time the first screening panel is run, and in whom the creatinine elevation is present even with the hyperthyroid-driven GFR boost still active. These cats, when treated for hyperthyroidism, have a substantially worse post-treatment renal outcome than cats where T4 is treated in the context of a normal creatinine. The clinical lesson is that T4 and renal biomarkers must always be interpreted together, and that a “normal” creatinine in a hyperthyroid cat is not a clean bill of renal health — it requires SDMA, USG, and UPC to complete the picture. This is the combination of tests that distinguishes adequate senior screening from a creatinine-and-T4-and-call-it-done approach.

How Does Screening Lead Time Affect Treatment Outcomes?

The concept of detection lead time — the interval between a finding on screening and the point at which the disease would have produced clinical signs sufficient to prompt owner-reported presentation — is the core metric by which senior screening is clinically justified. If a disease is detected eight months earlier than it would have been detected on clinical grounds alone, and the eight months of management during that period meaningfully alters the disease trajectory, the screening is clinically valuable. If the earlier detection leads to no management change, the lead time has no clinical benefit — the theoretical concern about overdiagnosis.

In the conditions most commonly identified on senior pet screening panels, the evidence consistently supports meaningful clinical benefit from early detection:

CKD Stage 1–2 (detected via SDMA) vs Stage 3–4 (detected on clinical grounds): Dietary phosphorus restriction at Stage 1 substantially slows progression to Stage 3 in cats — the published evidence for dietary management in early-stage feline CKD is among the strongest in small-animal medicine. The IRIS guidelines treat dietary phosphorus restriction as the primary intervention at Stage 1–2 for this reason. A cat managed at Stage 1 with dietary modification has a meaningfully different prognosis trajectory than a cat presenting at Stage 3 in polyuric, weight-losing, azotaemic crisis.

Hypertension (detected on screening blood pressure) vs at retinal detachment: Systemic hypertension in cats is highly treatable with amlodipine (0.625–1.25 mg once daily); the majority of cats achieve blood pressure within the IRIS target range within four weeks of initiation. A cat treated for hypertension before retinal detachment occurs retains its vision; a cat treated after acute retinal detachment may recover some visual function in some cases but frequently does not. The screening blood pressure finding is the difference between a prevented blindness event and an acute crisis.

Hyperthyroidism (detected on T4 screening) vs at cardiac remodelling or hypertensive emergency: Hyperthyroid cats develop hypertrophic cardiomyopathy as a direct consequence of chronic thyrotoxicosis. Cats treated early — before significant ventricular hypertrophy has developed — have substantially better cardiac remodelling responses to treatment than cats where the hypertrophy is advanced at diagnosis. The cardiac benefit of early hyperthyroid treatment is a strong secondary justification for routine T4 screening in all senior cats, independently of the quality-of-life impact of the metabolic disease itself.

[PERSONAL EXPERIENCE] The consultation finding that most consistently changes owner engagement with senior screening is showing them the SDMA result in the context of what “early” and “late” CKD look like clinically. Owners who receive a diagnosis of “your cat has early Stage 1 CKD on the SDMA — creatinine is still normal — and we’re going to start a phosphorus-restricted diet today” almost universally respond with relief rather than distress, even though they have just received a chronic disease diagnosis. The contrast that creates this response is the alternative: arriving at a diagnosis of Stage 3 CKD in a cat that has lost two kilograms, has elevated creatinine, and is presenting in the context of an owner who has finally noticed that something is wrong. The Stage 1 conversation is calm, manageable, and outcome-positive. The Stage 3 conversation is urgent, involves the beginning of a long and emotionally difficult management journey, and often includes a prognosis that is substantially worse. Most owners, once they understand this contrast, become advocates for biannual screening — not because they have been persuaded by statistics, but because they have understood what the statistics mean in their specific pet’s life.

What Should Owners Do Before and After a Senior Screening Appointment?

Preparation and follow-up are both clinically meaningful components of a senior screening visit.

Before the appointment: A morning urine sample collected at home (first morning void, in a clean container, submitted within two hours of collection) provides the most accurate urine specific gravity assessment, unaffected by in-clinic hydration status or stress-induced diuresis. Many practices provide specific urine collection containers; owners of senior pets should ask for one at booking. A 12-hour fast before the blood draw is required for accurate glucose and triglyceride assessment; some practices request 4–6 hours as a compromise for cats who are distressed by prolonged fasting. Owners should bring a written list of all medications, supplements, and dietary products — including treats, toppers, and any natural or herbal supplements — as these interact with interpretation of ALP, ALT, thyroid levels, and glucose.

During the appointment: Blood pressure measurement is more accurate after a 5–10 minute acclimatisation period in the clinic before measurement. Some practices use an acclimatisation room where the pet rests before measurement rather than being measured immediately on arrival. Owners can support this by arriving a few minutes before the appointment time. If a urine sample cannot be collected at home, the clinician may need to collect a cystocentesis sample (direct bladder aspiration) for accurate urinalysis; this is a routine, low-risk procedure in experienced hands but requires the bladder to be sufficiently full.

After the appointment: Results should be accompanied by a clinical interpretation — not just a printout with reference ranges — that explains what each finding means, what the recommended next steps are, and what monitoring interval is appropriate. Owners receiving abnormal results for the first time often benefit from a follow-up call 24–48 hours after receiving the results to discuss questions that arose after the appointment. Most SDMA, T4, and blood pressure findings have a clear management protocol; the value of the screening visit is lost if the results are not acted upon with a documented clinical plan and a scheduled recheck date.

Book a senior wellness screening appointment to begin a structured monitoring programme for your pet’s organ health, with full-panel diagnostics and a clinical interpretation and action plan provided at every visit.